Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2013 - 2016)

Amphastar Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $114000.0 for Q2 2016.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $114000.0 in Q2 2016; TTM through Dec 2023 was $114000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $2.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment eased to $114000.0 in Q2 2016 per AMPH's latest filing, from $217000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $217000.0 in Q1 2016 and bottomed at $4000.0 in Q3 2015.
• The 4-year median for Asset Writedowns and Impairment is $120000.0 (2013), against an average of $113555.6.
• Biggest YoY gain for Asset Writedowns and Impairment was 64.1% in 2015; the steepest drop was 69.23% in 2015.
• Year by year, Asset Writedowns and Impairment stood at $120000.0 in 2013, then tumbled by 35.0% to $78000.0 in 2014, then soared by 64.1% to $128000.0 in 2015, then declined by 10.94% to $114000.0 in 2016.
• Per Business Quant, the three latest AMPH Asset Writedowns and Impairment figures stand at $114000.0 (Q2 2016), $217000.0 (Q1 2016), and $128000.0 (Q4 2015).